PLX Protalix BioTherapeutics Inc. (DE)

0.43
0  0%
Previous Close 0.43
Open
Price To Book -1.06
Market Cap 63,210,859
Shares 148,382,299
Volume 694
Short Ratio 15.03
Av. Daily Volume 260,507

NewsSee all news

  1. Protalix (PLX) Completes Enrollment in Fabry Disease Study
  2. Protalix BioTherapeutics Completes Enrollment in the Phase III BRIGHT Clinical Trial of pegunigalsidase alfa (PRX 102) for the Treatment of Fabry Disease
  3. Protalix BioTherapeutics and Chiesi Farmaceutici S.p.A to Apply for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States
  4. Why Przetwórstwo Tworzyw Sztucznych Plast-Box S.A.'s (WSE:PLX) High P/E Ratio Isn't Necessarily A Bad Thing
  5. Protalix BioTherapeutics Appoints Dror Bashan as its New President and Chief Executive Officer and Director

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved May 1, 2012.
Taliglucerase alfa
Gaucher disease
Phase 3 trial 11 patients away from full enrolment.
Pegunigalsidase alfa (PRX-102)
Fabry disease
Phase 2 interim data released January 3, 2017. Full data released April 12, 2017. Company noted data were positive but results showed efficacy down on January data.
AIR DNase (PRX-110)
Cystic Fibrosis
Phase 2 data released March 13, 2018 - key endpoints met. Data presented at DDW Meeting - 67% of patients experienced a clinical response.
OPRX-106
Ulcerative Colitis
Phase 3 BRIDGE completion of enrolment announced December 17, 2018 with additional data due 2019. BLA filing due 1Q 2020.
Pegunigalsidase alfa (PRX-102) BRIDGE
Fabry disease
Phase 3 completion of enrolment announced June 17, 2019.
Pegunigalsidase alfa (PRX-102) - BRIGHT
Fabry disease

Latest News

  1. Protalix (PLX) Completes Enrollment in Fabry Disease Study
  2. Protalix BioTherapeutics Completes Enrollment in the Phase III BRIGHT Clinical Trial of pegunigalsidase alfa (PRX 102) for the Treatment of Fabry Disease
  3. Protalix BioTherapeutics and Chiesi Farmaceutici S.p.A to Apply for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States
  4. Why Przetwórstwo Tworzyw Sztucznych Plast-Box S.A.'s (WSE:PLX) High P/E Ratio Isn't Necessarily A Bad Thing
  5. Protalix BioTherapeutics Appoints Dror Bashan as its New President and Chief Executive Officer and Director
  6. Edited Transcript of PLX earnings conference call or presentation 6-May-19 12:30pm GMT
  7. Przetwórstwo Tworzyw Sztucznych Plast-Box S.A. (WSE:PLX) Delivered A Weaker ROE Than Its Industry
  8. Protalix (PLX) Reports Q1 Loss, Tops Revenue Estimates
  9. Protalix: 1Q Earnings Snapshot
  10. Protalix BioTherapeutics Reports 2019 First Quarter Results and Provides Corporate Update
  11. Protalix (PLX) to Report Q1 Earnings: What's in the Cards?
  12. Is Protalix BioTherapeutics, Inc.'s (NYSEMKT:PLX) CEO Being Overpaid?
  13. Protalix BioTherapeutics to Hold First Quarter 2019 Financial Results and Corporate Update Conference Call on May 6, 2019
  14. Do Options Traders Know Something About Protalix (PLX) Stock We Don't?
  15. Protalix BioTherapeutics Reports 2018 Full Year Results and Provides Corporate Update
  16. Protalix Biotherapeutics, Inc. to Host Earnings Call
  17. Protalix BioTherapeutics to Postpone the 2018 Financial Results and Corporate Update Conference Call
  18. When Will Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Turn A Profit?
  19. Protalix BioTherapeutics to Hold Full-Year 2018 Financial Results and Corporate Update Conference Call on March 14, 2019